啥利好啊。

Kite Pharma (NASDAQ:KITE) +34.5% AH after announcing positive results in a clinical study of patients receiving Kite's treatment for non-Hodgkin's lymphoma.

The clinical trial funded by Kite  and  conducted by the Surgery Branch of the National Cancer Institute found that in 12 of 13 evaluable patients with  advanced B-cell  malignancies receiving Kite's anti-CD19 CAR T cell therapy  resulted in complete  remission in eight patients and partial remission  in four patients.

Based on the study, Kite says it plans to file an Investigational New Drug Application during Q4.

是有什么利好么，涨那么多

卧槽 捡钱了。。。。@我是_一级棒 还记得这个票子么

我擦

同错过